Page Image

HER2 Breast Cancer

Back to Homepage
EU Approves Enhertu for HR-Positive, HER2-Low, HER2-Ultralow Metastatic Breast Cancer Following Endocrine Therapy
Enhertu approved in the EU for HR+, HER2-low, -ultralow metastatic breast cancer, showing PFS benefit over chemotherapy.
Advertisement

Expert Interviews

Advertisement
Advertisement
Latest Breast Cancer News

March 26, 2025